BioSpace News Archive

FDA Advisory Committee Scheduled to Review Lipocin

Drug Development

One-Time CAR-T Leader Juno Shows Off Promising New Clinical Data

The company submitted 15 abstracts to be presented at the upcoming ASH Conference.

November 1, 2017

·

12 min read

Policy

MiMedx Agrees to Lawsuit Settlement With Halo Wound Solutions

MiMedx announced today that the Company has agreed to a confidential settlement of the lawsuit the Company filed against BioResolutions LLC d/b/a Halo and one of the Halo executives.

November 1, 2017

·

4 min read

Genetown

Pressure BioSciences Initiates Aggressive Marketing and Sales Strategy Expected to Drive Significant Expansion Into China

Pressure BioSciences announced that Professor Tiannan Guo’s laboratory at Westlake Institute for Advanced Study (“WIAS”) has been named the Company’s first Center of Excellence (“CoE”) in China.

November 1, 2017

·

6 min read

Pharm Country

Fortress Biotech Announces Proposed Public Offering of Series A Preferred Stock

All of the shares to be sold in the offering will be offered by Fortress.

November 1, 2017

·

4 min read

Drug Development

Novartis Presents Data at ASH for Patients With Serious Blood Disorders Like Lymphoma, Leukemia and Sickle Cell Disease

The 59th American Society of Hematology Annual Meeting & Exposition will be held in Atlanta on December 9-12.

November 1, 2017

·

12 min read

Business

Cascadian Therapeutics to Report Third Quarter 2017 Financial Results on November 8, 2017

Management will host a conference call and live audio webcast to discuss the results and provide a general corporate update

November 1, 2017

·

1 min read

Drug Development

Inovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhibitor

Phase 1b/2a clinical trial combines Regeneron’s PD-1 inhibitor cemiplimab and Inovio’s T cell activator INO-5401 in brain cancer.

November 1, 2017

·

6 min read

Business

Chembio to Host Conference Call to Discuss Third Quarter 2017 Financial Results

The CEO and CFO will host a conference call and webcast at 4:30 p.m. ET on November 8, 2017 to discuss these results.

November 1, 2017

·

3 min read

Drug Development

Meta-Analysis Using Real-World Data Evaluates Safety Profile of Takeda’s Entyvio (vedolizumab) in Patients With Moderate to Severe Ulcerative Colitis or Crohn’s Disease

New meta-analysis provides a comprehensive view of real-world data and furthers understanding of Entyvio as an important treatment option for patients with ulcerative colitis or Crohn’s disease.

November 1, 2017

·

12 min read

Drug Development

TWi Biotech Presents Positive Results From AC-201 CR Phase II Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting

The trial demonstrated taking 100mg AC-201CR twice a day in combination with 40mg febuxostat significantly increased the treatment success rate from 55% to 64% and from 27% to 39% defined as reaching serum uric acid concentration below 6mg/dL and 5mg/dL in 4 weeks, respectively.

November 1, 2017

·

5 min read